Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(62)

カスタマーフィードバック(12)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 M1f6U2N6fG:2b4jpZ{BCe3OjeR?= MoHLNVAhdk1? MoXTO|IhcA>? NFexS2hFVVOR MoH1VI91\W62aXH0[ZMh[2GvcITveIhm[2mwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 NIHpUHIzPDlyMEi3Ny=>
HT-29 NVXyNnlGS3m2b4TvfIlkKEG|c3H5 MWGxNEBvVQ>? MUi3NkBp NWnrN4NGTE2VTx?= MYHQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl? MnHCNlQ6ODB6N{O=
HT-29 NH7PN2ZEgXSxdH;4bYMhSXO|YYm= NWjyVIp6OTBibl2= MmLTO|IhcA>? Ml;2SG1UVw>? M1yycnBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NVvBUIV[OjR7MEC4O|M>
PC3 Mke5T4lv[XOnIFHzd4F6 NUDsUoxtOTByIH7N NEnjN|MyKGh? MVXEUXNQ NIm0PFVRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> MlvyNlE6Pzh4OEO=
PC3 NFfOfYRMcW6jc3WgRZN{[Xl? NYXaNlRbOTByIH7N NHTSZ2syKGh? Mn3YSG1UVw>? M{HpbGRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w NGPEO5UzOTl5OE[4Ny=>
PC3 MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m4V|EvPSEQvF2= M3z2fVEhcA>? NHn1dZlFVVOR M3O5OWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?= M2\MRVIyQTd6Nkiz
HEK293 M3TIVmZ2dmO2aX;uJGF{e2G7 MV6xNFAhdk1? MVm4JIg> MUPEUXNQ NXXIO5Q2UW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N NGjMSHEzOTV|OUOwNS=>
BT-20 MnHqT4lv[XOnIFHzd4F6 Mn6xNlAh|ryP NIPWRXJFVVOR Ml\sSI9meyCwb4SgbY5pcWKrdDDtWG9TSzJiZHXw[Y5l\W62IIDBb3QhWzR5MzDwbI9{eGixconsZZRqd25? NHf2Z4YzOTN3M{W1NS=>
U937 NIDhOIhCdnSrYnHjeIVzcWGuIFHzd4F6 M3iwOVUxKM7:TR?= NX;CTGFuPDhiaB?= NVnMTFdqTE2VTx?= M3q3SGlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= NUDCZ3M2OjFzNEKxNFY>
U937 M1rSZWFvfGmkYXP0[ZJq[WxiQYPzZZk> MoXQOVAh|ryP MUm0PEBp NEfaTmNFVVOR NUTnWFd6TG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= NV3weZBQOjFzNEKxNFY>
U937 NH\XVm5CdnSrYnHjeIVzcWGuIFHzd4F6 NUfZSnp4PTBizszN MXm0PEBp NYHIeVN6TE2VTx?= MnnwSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM> MYqyNVE1OjFyNh?=
MCF-7 M2\3T2F2fG:yaHHnfUBCe3OjeR?= MUmzNEBvVQ>? NHHBcY41KGh? MofISG1UVw>? M4ewdWlv\HWlZYOgZZV1d3CqYXf5 NEG3NXIzODB{OEGzOC=>
U87MG NWHtc3k3U2mwYYPlJGF{e2G7 NUTP[I9[OSEQvF2= M{P5T|YhcA>? NV7Re3lxTE2VTx?= MmHTVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? NUG5R3VROTl6NEi0NFQ>
U87MG Ml3jT4lv[XOnIFHzd4F6 MonKNUDPxE1? NWTFTmt6PiCq Mn\kSG1UVw>? NFS2TIJRd3SnboTsfUBqdmirYnn0d{A1TUKSMTjUO|AqKHCqb4PwbI9zgWyjdHnvci=> MkPXNVk5PDh2MES=
U87MG M2XxTGtqdmG|ZTDBd5NigQ>? MkDuNUDPxE1? MmfROkBp MonDSG1UVw>? NEDv[HdFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= NYHLSnRLOTl6NEi0NFQ>
U87MG M{DtRmtqdmG|ZTDBd5NigQ>? NX7vbndMOSEQvF2= NWnDdoFEPiCq MnW2SG1UVw>? M3jrVWRw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN|cwPDZrIIDoc5NxcG:{eXzheIlwdg>? NVLaV3QxOTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb NUL0boRPSXW2b4DoZYd6KEG|c3H5 M1\zPFAvOiEQvF2= M{f3PVI1KGh? NHG5V5RFVVOR MVjJcoR2[2W|IHH1eI9xcGGpeR?= M1vn[VE5OzlzOUS5
COS7 cells expressing EGFP-LC3 MoW1RZV1d3CqYXf5JGF{e2G7 M3fZN|AvOiEQvF2= M1;IUFI1KGh? M4HyfWROW09? NH\QcWJKdmS3Y3XzJIF2fG:yaHHnfS=> MW[xPFM6OTl2OR?=
H4 M3XKc2Z2dmO2aX;uJGF{e2G7 NF;lcnkxNjJizszN MnvMNlQhcA>? M2fuT2ROW09? NUTaTZpoUW6lcnXhd4V{KHSqZTDyZZRqdyCxZjDsbYdpfCClaHHpckA{KHO3YoXubZQhOiC2bzDsbYdpfCClaHHpckA{KHO3YoXubZQhOSCrbjDoeY1idiCKNDDj[Yxtew>? M1fUclE5ODJ2NUi0
HeLa Mo\5SpVv[3Srb36gRZN{[Xl? M3yzb|ExOCCwTR?= M3;2UFM3KGh? MX;EUXNQ M121[mlv\HWlZYOgSnJDKEt{MEm1VEwhXDJyOUjMMEBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> NXjDfGZoOTd3NkOzPFU>
HeLa MXHGeY5kfGmxbjDBd5NigQ>? M{f5[VExOCCwTR?= NV7ubXN[OzZiaB?= MWPEUXNQ Mn;NTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MV6xO|U3OzN6NR?=
HeLa NGLZO4hHfW6ldHnvckBCe3OjeR?= MVuxNFAhdk1? NUSxT5RoOzZiaB?= MmLhSG1UVw>? MVrJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= NIflN3AyPzV4M{O4OS=>
SYF M1;GPWZ2dmO2aX;uJGF{e2G7 MUKxNFAhdk1? MVuyOEBp MmHwSG1UVw>? MV7JcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= Ml61NVc2PjN|OEW=
SYF NF\YNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjNbYJKOTByIH7N NV\zfpY5OjRiaB?= NHPwT5VFVVOR NH;CTmVKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz MlPrNVc2PjN|OEW=
HEK293T Mk[xRY51cX[rcnHsJGF{e2G7 M3flNlEhdk1? NHjxdmw1KGR? MWHEUXNQ MUDJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= MoPKNVc1QDV3MEG=
HEK293T MnjkRY51cX[rcnHsJGF{e2G7 MXqxJI5O NHm4TlI1KGR? M1WxPWROW09? MXvJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?= NWH3cG9POTd2OEW1NFE>
PBMC NFz1XXlHfW6ldHnvckBCe3OjeR?= MVuxJI5O NGO2VVEyPCCm MmGzSG1UVw>? NUmw[IQ5WmWmdXPld{BES1J3IHTlcpNqfHl? NFHMSYIyPzR6NUWwNS=>
PBMC NXvpVYRrTnWwY4Tpc44hSXO|YYm= MWmxJI5O M2D3W|E1KGR? MUDEUXNQ MUXEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> M2npdFE4PDh3NUCx
HEK293 cells NWTmZVdKU2mwYYPlJGF{e2G7 M33NVlUxKG6P M4DOblQ2KG2rbh?= NHf3eotFVVOR NEPhToNKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P NIXUNJMyPzN3MEm1Ny=>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NVnGToxbTnWwY4Tpc44hSXO|YYm= NGjZcW8yODBibl2= M13rTlQhcA>? NWf6ZXVJTE2VTx?= M320emlv\HWlZYOgcJVkcW[ncnHz[UBxem:2ZXnuJJRz[W6|LYPwcIlkcW6pIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy|IITyZY5{\mWldHXkJJdqfGhiTj3seYMh[W6mIFOtcJVk M4XtSFE4OTJ6Mk[y
Human mixed lymphocyte MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7aOUBvVQ>? M334VGROW09? M4nqZmlEPTB;MT62JI5ONg>? MkW0NVYyQDV6NkW=
Lewis rat lymph node cells M1f1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLPOUDPxE1? NV;uOG01TE2VTx?= NVTCeHVSUUN3ME2yMlYh|ryP NV\v[YdMOTZzOEW4OlU>
cells from the thymus of normal BALB/c mice M3nhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDxXXIyOCCwTR?= NXzGfHN{PzJiaB?= MlvsSG1UVw>? MWHJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P NIPueG0yODB{MUm0PC=>
MRK-nu-1 NFXVZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m3RmlEPTB;MD64OFUheE1? M4D6RXNCVkeHUh?=
OCUB-M MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfOTWM2OD13LkK0JJBO M1zGVXNCVkeHUh?=
SF539 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\0TWlEPTB;MUGuOkBxVQ>? NEDw[3JUSU6JRWK=
ES4 NILPU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qxemlEPTB;MkGuOUBxVQ>? NVvqTnBzW0GQR1XS
RL95-2 NWLrTZF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDXTWM2OD1zMEegdG0> NGm2RZVUSU6JRWK=
LC-2-ad Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHwWVRKSzVyPUSyN{BxVQ>? M1HiT3NCVkeHUh?=
Daudi NVvneJM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXGTWM2OD12M{SgdG0> NHGwUXlUSU6JRWK=
NTERA-S-cl-D1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTVTWM2OD12NEOgdG0> NUHuRlVWW0GQR1XS
OS-RC-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTMXpY1UUN3ME22OVIheE1? NULnOnJxW0GQR1XS
VA-ES-BJ M4\BO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17CPGlEPTB;N{KzJJBO NFfOSY9USU6JRWK=
GR-ST NYr0Z4dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO1TWM2OD16NE[gdG0> M3f0W3NCVkeHUh?=
SW872 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTh2NjDwUS=> M2ixSXNCVkeHUh?=
NOS-1 M1zDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTh5MTDwUS=> NVLCUpg2W0GQR1XS
MC116 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37iSWlEPTB;OUi1JJBO NGDMbpdUSU6JRWK=
NCI-H1355 M3rhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrPbHdLUUN3ME2xMlAyKG6P MV7TRW5ITVJ?
RPMI-8226 NVHrdoZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH5TWM2OD1zLkG5JI5O MVzTRW5ITVJ?
TE-15 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjpTWM2OD1zLkO2JI5O MXvTRW5ITVJ?
Ramos-2G6-4C10 NUfPO3dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;C[IFKSzVyPUGuOFYhdk1? MnHpV2FPT0WU
KU812 M374bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PudmlEPTB;Mj6wNUBvVQ>? NGjjNmFUSU6JRWK=
EW-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjk[HVKSzVyPUKuNVchdk1? M2rFWXNCVkeHUh?=
KS-1 NX:yWFhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJwNEWgcm0> MV\TRW5ITVJ?
SK-LMS-1 NFjPW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJwNEmgcm0> NFq3OndUSU6JRWK=
TGBC1TKB MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHnTWM2OD1{Lk[5JI5O NIexUY1USU6JRWK=
TE-6 MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f2b2lEPTB;Mj63O{BvVQ>? MV3TRW5ITVJ?
ETK-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJwOEKgcm0> M{HpSXNCVkeHUh?=
BE-13 M2T6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknETWM2OD1{Lkm5JI5O M2HXWXNCVkeHUh?=
A3-KAW NVHZXIhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXnTWM2OD1{Lkm5JI5O MWfTRW5ITVJ?
TE-10 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTNwMzDuUS=> NF;p[ohUSU6JRWK=
DOHH-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PDO2lEPTB;Mz6zOUBvVQ>? Mn7jV2FPT0WU
ES6 MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3kVFRKSzVyPUOuOFMhdk1? NGfRbFZUSU6JRWK=
OPM-2 NV;KOo9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH3TWM2OD12LkG1JI5O MofrV2FPT0WU
SH-4 NEnYSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH6PVlKSzVyPUSuN|Qhdk1? M{jVUXNCVkeHUh?=
NB13 NXfBWHdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPUNIs1UUN3ME20MlM3KG6P M3SxS3NCVkeHUh?=
HUTU-80 M33QZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTpeWYzUUN3ME20MlQzKG6P M4fjUnNCVkeHUh?=
CCRF-CEM MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv4Rmd3UUN3ME20Mlk1KG6P NXH4eXhnW0GQR1XS
TGBC24TKB MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfmXZVKSzVyPUWuOVEhdk1? NUfoW|l4W0GQR1XS
697 NEPJVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTZwMkigcm0> MmT5V2FPT0WU
J-RT3-T3-5 M1H1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr1TWM2OD14LkS2JI5O NGTGR21USU6JRWK=
KALS-1 M1\ac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\nRWlEPTB;Nj61OkBvVQ>? MVjTRW5ITVJ?
no-10 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvsTWM2OD15LkK5JI5O NYXCWmxZW0GQR1XS
SK-NEP-1 Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTYSmxKSzVyPUiuO|khdk1? M4jjRXNCVkeHUh?=
L-540 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYOyS4VRUUN3ME2xNE41OiCwTR?= MnjGV2FPT0WU
JiyoyeP-2003 NIHpSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH1TWM2OD1zMD65OEBvVQ>? NYrvcYVbW0GQR1XS
HH M{jmcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T4TWlEPTB;MUGuN|khdk1? MXTTRW5ITVJ?
SR NXfoOXdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS0eWRxUUN3ME2xNU41PSCwTR?= M3T6VXNCVkeHUh?=
QIMR-WIL MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTzTWM2OD1zMT64OUBvVQ>? MkXCV2FPT0WU
A4-Fuk MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV6wV5lLUUN3ME2xN{4yOiCwTR?= NH7tTYZUSU6JRWK=
CESS NHzCdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLJN2xKSzVyPUGzMlE{KG6P NX31OnY{W0GQR1XS
KE-37 MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTXZYZKSzVyPUG2MlA4KG6P M2LlRnNCVkeHUh?=
SK-UT-1 NVzkOWMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF4LkixJI5O M{j0OHNCVkeHUh?=
SIG-M5 NXrvN2ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrRbG5mUUN3ME2xO{4zPSCwTR?= M2fwU3NCVkeHUh?=
HT NYj0fHgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF5Lk[gcm0> NEHhNHpUSU6JRWK=
DEL NUDCNmtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\0SWlEPTB;MUeuPVkhdk1? NVrtPGVDW0GQR1XS
SK-PN-DW NWm0U|dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr1cW5JUUN3ME2yNE4zOyCwTR?= NHnBTlZUSU6JRWK=
RPMI-8402 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi5W3lKSzVyPUKxMlc4KG6P NFjV[|hUSU6JRWK=
RPMI-6666 NF3oPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfITWM2OD1{ND60NkBvVQ>? NGTiSY9USU6JRWK=
NCI-H720 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGOxS|RKSzVyPUK1MlQyKG6P M{TZcnNCVkeHUh?=
EW-16 NUPXTW86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm3[W1DUUN3ME2yOk45PyCwTR?= M{\aWXNCVkeHUh?=
BL-70 NYmyZ2Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;BfmgyUUN3ME2yPE4{QCCwTR?= M{PRPXNCVkeHUh?=
SF126 M3HEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XVXWlEPTB;M{CuN|ghdk1? NHvMfnhUSU6JRWK=
BC-1 MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnZfpNMUUN3ME2zNU4zPiCwTR?= M2\2SHNCVkeHUh?=
MHH-PREB-1 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\XTYZKSzVyPUOyMlQ1KG6P MorJV2FPT0WU
A101D NFjZdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTN{Lk[yJI5O M4DKfHNCVkeHUh?=
NMC-G1 NV3sdJROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfxWmFKSzVyPUOzMlY4KG6P Ml7wV2FPT0WU
LB1047-RCC NWfUPZVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTN2Lk[5JI5O NXvpeJR2W0GQR1XS
EM-2 M1Pac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTFSm1KSzVyPUO4MlU{KG6P NYXERo9NW0GQR1XS
COLO-684 M4T5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPHeIRKSzVyPUO5Mlghdk1? NHvDe4JUSU6JRWK=
Becker NWLKUGJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fYV2lEPTB;NEGuNFUhdk1? NHvJNm5USU6JRWK=
BL-41 NVzGXolxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTR|Lk[2JI5O MUDTRW5ITVJ?
MDA-MB-134-VI MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[1XGlEPTB;NESuNFIhdk1? NVOwXFBDW0GQR1XS
L-363 NGr0O4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXtXnNKSzVyPUS0Mlc{KG6P NFPObZBUSU6JRWK=
ECC4 NX7qSmFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV64ZlNmUUN3ME20OE44QCCwTR?= MWXTRW5ITVJ?
A388 M3e3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTR2LkiyJI5O MoD1V2FPT0WU
HEL NYHHVlZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTR7Lke5JI5O NW[0XVRPW0GQR1XS
RKO MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTVyLkK5JI5O M2LsZXNCVkeHUh?=
KINGS-1 NXe1OXhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTPTWM2OD13MT61OUBvVQ>? NGfVcIhUSU6JRWK=
EB-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTTTWM2OD13Mj62O{BvVQ>? NVK4XnMyW0GQR1XS
ARH-77 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTV{Lkigcm0> Ml64V2FPT0WU
GCIY MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jDb2lEPTB;NUOuOFYhdk1? NH7UVFFUSU6JRWK=
NCI-H1304 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\ab|hCUUN3ME21O{4zOiCwTR?= Ml\nV2FPT0WU
KARPAS-299 M4nwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTZzLkiyJI5O MYDTRW5ITVJ?
IA-LM NWf5OVU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK2TWM2OD14OD6xN{BvVQ>? MV;TRW5ITVJ?
GI-1 NYjCZZdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK4TWM2OD15MD6zPUBvVQ>? MVzTRW5ITVJ?
TE-11 NU\TU5ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTd5LkG3JI5O NUf1eW9PW0GQR1XS
LS-411N MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjoS2tkUUN3ME23O{42PyCwTR?= NEnsTXRUSU6JRWK=
no-11 MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTh|LkK0JI5O M{npUHNCVkeHUh?=
MV-4-11 NF\aWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfTTWM2OD16Mz63N{BvVQ>? M{LHU3NCVkeHUh?=
BV-173 MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojxTWM2OD16Mz65O{BvVQ>? MX7TRW5ITVJ?
CMK MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr3OJBKSzVyPUi0MlE3KG6P NIGwXINUSU6JRWK=
LC4-1 M37PO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjMN2ZKSzVyPUi2MlczKG6P NHLKToRUSU6JRWK=
COR-L279 M{DOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXzTWM2OD16Nz6yOUBvVQ>? MUnTRW5ITVJ?
NCI-H209 NVjFTmtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Wzb2lEPTB;OEeuOFEhdk1? MWPTRW5ITVJ?
Raji NWDlbGRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTh7LkeyJI5O NV7QfXZmW0GQR1XS
LB996-RCC M1vqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qxdWlEPTB;OUOuOFMhdk1? NFfSc5lUSU6JRWK=
NCI-H526 M1;uOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P1bWlEPTB;OUOuOVkhdk1? MWfTRW5ITVJ?
KGN NF;kcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfrTWM2OD17Nj6yPUBvVQ>? NWT0NlZWW0GQR1XS
MOLT-4 NFjXVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPPOHFKSzVyPUm2Mlc6KG6P MX7TRW5ITVJ?
PF-382 MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnS4TWM2OD17Nj63PUBvVQ>? MkHMV2FPT0WU
BC-3 M4G3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTmTWM2OD17OT6xPEBvVQ>? MnzjV2FPT0WU
KARPAS-422 NH3mdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFyMj6wPUBvVQ>? NWW3XoQ4W0GQR1XS
SBC-1 NHHKN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfDTWM2OD1zMEeuO|Uhdk1? NITWdYpUSU6JRWK=
LC-1F NITW[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfxSJZKSzVyPUGwPE4xPSCwTR?= M1LVNHNCVkeHUh?=
GB-1 MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXNTWM2OD1zMEmuNFIhdk1? M1:3NnNCVkeHUh?=
SNB75 M4\W[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfrTWM2OD1zMUmuOlkhdk1? NVnrR4NlW0GQR1XS
BB65-RCC Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LIZWlEPTB;MUG5Mlk{KG6P M1fycHNCVkeHUh?=
NCI-N87 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\kdWlEPTB;MUKxMlk5KG6P NXLuUVhWW0GQR1XS
IST-MEL1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3RcmpKSzVyPUGyNk4{QCCwTR?= M2PQXnNCVkeHUh?=
HOP-62 NXrEbpdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF{Nj64PUBvVQ>? Mn32V2FPT0WU
ACN NULjNXhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zXUWlEPTB;MUS2Mlc2KG6P M2PnUHNCVkeHUh?=
DMS-114 NXXrUYFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF3MD62O{BvVQ>? NYrudVVPW0GQR1XS
MLMA NVHFXYRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\DdmlEPTB;MUW5Mlg5KG6P MkDqV2FPT0WU
HT-144 NVPXTIdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETBe3FKSzVyPUG2OU41OyCwTR?= MnrEV2FPT0WU
C2BBe1 M3[zOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF4Nz63OkBvVQ>? MYTTRW5ITVJ?
L-428 MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuy[G5KSzVyPUG3O{44KG6P MkL1V2FPT0WU
DU-4475 NVjmRmZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkCxTWM2OD1zOEeuOlghdk1? MY\TRW5ITVJ?
CP67-MEL M3f1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDE[3Q1UUN3ME2xPVkvOzhibl2= MXfTRW5ITVJ?
MEG-01 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnK4TWM2OD1{MEGuPVYhdk1? NVvOXHIxW0GQR1XS
IST-SL2 M2PrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHVS2NKSzVyPUKwPE43OyCwTR?= NUi5fmdbW0GQR1XS
ES8 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHkUnhPUUN3ME2yNlUvQTRibl2= M3\lPHNCVkeHUh?=
COLO-800 NHHTTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\XVmlEPTB;MkO1MlI5KG6P M3PyXHNCVkeHUh?=
MFH-ino MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXCTWM2OD1{M{WuPFQhdk1? NIrPO2tUSU6JRWK=
OVCAR-4 M{\SUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrx[JVKSzVyPUKzO{4zPCCwTR?= NWjuSGFMW0GQR1XS
PSN1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4flcWlEPTB;MkSyMlcyKG6P NF3GVJNUSU6JRWK=
EW-12 MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfzT3VMUUN3ME2yOFMvOSCwTR?= NWf2T4RpW0GQR1XS
HCC1599 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnaTWM2OD1{NkGuOFchdk1? MVLTRW5ITVJ?
SJSA-1 M37FXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DLUWlEPTB;MkexMlQ3KG6P MYfTRW5ITVJ?
ST486 NFHCSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HC[mlEPTB;Mkm2MlE1KG6P NGLkPFdUSU6JRWK=
NOMO-1 M4rmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH2clFKSzVyPUOwNE4zOSCwTR?= MVfTRW5ITVJ?
MN-60 NW[0W|N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTNyNT6zNkBvVQ>? NYPBTohFW0GQR1XS
HCC1187 NI\sWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe0VotKSzVyPUOwO{4zPSCwTR?= M2jyb3NCVkeHUh?=
SW982 NVj0[VdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LzemlEPTB;M{G0Mlc2KG6P MX;TRW5ITVJ?
LB647-SCLC NXe1eld3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTN{OD63NUBvVQ>? NUDmNXdQW0GQR1XS
HC-1 MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfXTWM2OD1|M{WuOUBvVQ>? M1LjbnNCVkeHUh?=
EHEB M2G0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojTTWM2OD1|M{euOVIhdk1? NUnvXW91W0GQR1XS
TUR M3PUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjoTWM2OD1|NkOuPVUhdk1? M2nxT3NCVkeHUh?=
LU-139 NUPGWXl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi4WYtsUUN3ME2zO|gvODJibl2= NXPZeohIW0GQR1XS
NB1 MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTN6ND60OUBvVQ>? MorHV2FPT0WU
BB30-HNC MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnWTWM2OD1|OEiuN|Ihdk1? NHfuTWRUSU6JRWK=
HAL-01 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;FTWM2OD1|OEmuNlYhdk1? NXvDepVvW0GQR1XS
K5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS0PIttUUN3ME20NVEvOzdibl2= MnX4V2FPT0WU
MZ2-MEL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTRzMz62OEBvVQ>? NFzjfVFUSU6JRWK=
RXF393 NUm3UldnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTRzNj60OUBvVQ>? MkDYV2FPT0WU
NCI-H1648 M{Dufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[wZpNWUUN3ME20NVcvPTNibl2= MYPTRW5ITVJ?
TE-12 M2HuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13CNmlEPTB;NEO0MlI3KG6P MYnTRW5ITVJ?
EoL-1- M4TtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml73TWM2OD12M{euPVghdk1? NYflcHhPW0GQR1XS
JAR MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPJfpJCUUN3ME20N|gvPjJibl2= NWrUNFROW0GQR1XS
DSH1 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv5TWM2OD12NUiuPVEhdk1? MXrTRW5ITVJ?
NCI-H187 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\nNmU{UUN3ME20OlIvQDFibl2= M{XnUXNCVkeHUh?=
HCE-4 M1G4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfQUVd7UUN3ME20O|cvPjZibl2= MnPrV2FPT0WU
8-MG-BA MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\kTWM2OD13OEGuOVIhdk1? MUnTRW5ITVJ?
KLE NVGw[4Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfoS41KSzVyPUW4OU4zKG6P NFuxb|RUSU6JRWK=
KNS-42 NXzlPVNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXVdWZQUUN3ME21PFYvQDFibl2= MUXTRW5ITVJ?
MSTO-211H MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vYfWlEPTB;NkC5Mlc1KG6P MV;TRW5ITVJ?
GDM-1 NV7hbmJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHHSng6UUN3ME22NVQvODlibl2= MlTxV2FPT0WU
TE-1 NGLIZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonETWM2OD14NE[uNVIhdk1? NEXse3VUSU6JRWK=
BT-474 M2Pzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\aNGlEPTB;NkS3MlA3KG6P NWjaRXZSW0GQR1XS
KARPAS-45 M{H0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHpcG5KSzVyPU[0O{43KG6P NIfsRndUSU6JRWK=
MOLT-16 M{XyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTkTWM2OD14NEeuPVMhdk1? NE\1cnVUSU6JRWK=
KURAMOCHI Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTZ3Nz61NUBvVQ>? MmrHV2FPT0WU
K-562 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGwTWM2OD14NkmuOVEhdk1? M1K4[HNCVkeHUh?=
EKVX NHKwWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTZ5Mj63NUBvVQ>? NV6xUo54W0GQR1XS
GAK NWi1OnNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL6NJdJUUN3ME22O|UvOyCwTR?= M{fsbHNCVkeHUh?=
NCI-SNU-5 NHL2Xm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnrVWFKSzVyPU[5NE4xOSCwTR?= MXnTRW5ITVJ?
NCI-H2126 NX;uV44zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfSS4VnUUN3ME23NlYvQDdibl2= Mom1V2FPT0WU
CTV-1 NWHKRWk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPFTWM2OD15NESuPUBvVQ>? MYHTRW5ITVJ?
SW962 M{PVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTd2OD60OEBvVQ>? NHnQTGZUSU6JRWK=
MONO-MAC-6 MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\CWWlEPTB;N{W2Mlk{KG6P NHfyclRUSU6JRWK=
NCI-H748 NV\rTpQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLPTWM2OD15NUiuPVkhdk1? M2n0TXNCVkeHUh?=
NCI-H524 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTd6MD63N{BvVQ>? M2\JUnNCVkeHUh?=
LS-123 M2PscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TUXmlEPTB;N{m1MlY6KG6P M3\JXXNCVkeHUh?=
NB7 NUPLXmxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPjbVRKSzVyPUixOE4yPCCwTR?= NYK5TWFEW0GQR1XS
LS-1034 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki5TWM2OD16MkiuPVghdk1? MknKV2FPT0WU
TE-5 NVK4[lhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjKVJBOUUN3ME24PFMvPTZibl2= NYnxfYJGW0GQR1XS
A704 M4HGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnmPZF1UUN3ME24PVkvOTVibl2= M4jHS3NCVkeHUh?=
TK10 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf6SJRKSzVyPUmxOk4xOyCwTR?= MVzTRW5ITVJ?
NCI-H345 M4LYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTl2Mz6yNkBvVQ>? M2HQcnNCVkeHUh?=
CGTH-W-1 NFT2emNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm2TWM2OD17NEiuNVMhdk1? MoDRV2FPT0WU
NCI-H510A M3LrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlexTWM2OD17OEWuNVIhdk1? NI\lZWtUSU6JRWK=
NCI-H1963 Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LuR2lEPTB;MT6wN|I6OiEQvF2= M2rWNnNCVkeHUh?=
SCC-3 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXDTWM2OD1zLkCzOFE1KM7:TR?= Mn7YV2FPT0WU
EW-11 NU[0VI1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T5XGlEPTB;MT6wPFc1OyEQvF2= MXvTRW5ITVJ?
CPC-N MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFwMEi4JO69VQ>? NGnJ[GNUSU6JRWK=
NCI-H1417 NE\VbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\DbWRtUUN3ME2xMlEzOjZizszN MmH1V2FPT0WU
DG-75 M3v6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLuboNKSzVyPUGuNVYzQDVizszN MlO2V2FPT0WU
HD-MY-Z MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFwMU[0NVYh|ryP M13QSXNCVkeHUh?=
ATN-1 NHLTSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDvdXJSUUN3ME2xMlI3OjB7IN88US=> M3HoNnNCVkeHUh?=
KM-H2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTOTWM2OD1zLkK2OFA5KM7:TR?= NH:3cpJUSU6JRWK=
NCI-H2081 M1ywSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\jb2lEPTB;MT6yOlY{PyEQvF2= MVzTRW5ITVJ?
HL-60 NGDMOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DGOmlEPTB;MT6yOlk2QSEQvF2= M3XTVXNCVkeHUh?=
DB NH34fGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXjTWM2OD1zLkK3NlQzKM7:TR?= MnvzV2FPT0WU
NCI-H1522 NVPsTms3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm4UVVKSzVyPUGuNlg5QDdizszN NUTBSYZmW0GQR1XS
AM-38 NHHlXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLvPVBKSzVyPUGuN|A4OiEQvF2= NUjXOmxmW0GQR1XS
NCI-H446 NXrsUFBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n4N2lEPTB;MT6zNlEzOSEQvF2= MXfTRW5ITVJ?
SU-DHL-1 M2\0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTFwM{K4NFEh|ryP NWHBNIZjW0GQR1XS
NH-12 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHL1d2ZKSzVyPUGuN|Y{PzRizszN MnXIV2FPT0WU
DMS-79 M4nzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkWzTWM2OD1zLkO2PFY3KM7:TR?= NWXMVJlPW0GQR1XS
NCI-H716 M1TtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fiT2lEPTB;MT6zPFk5PiEQvF2= MWDTRW5ITVJ?
ML-2 MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwNEG1Nlkh|ryP MlvBV2FPT0WU
NB10 NEnLOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFwNE[2N|Ih|ryP MnvoV2FPT0WU
ONS-76 M4q5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KwXGlEPTB;MT61N|U3QSEQvF2= NFS2TYZUSU6JRWK=
LOUCY NHPienhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwNUS2OVch|ryP M{jtTXNCVkeHUh?=
SCLC-21H NFuxfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjxO5I6UUN3ME2xMlU5PTh{IN88US=> M{XTOHNCVkeHUh?=
TGW Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXITWM2OD1zLk[zPVc2KM7:TR?= NVm4Vml3W0GQR1XS
LXF-289 M3rOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG5VIlKSzVyPUGuO|MzPjhizszN Ml[4V2FPT0WU
BB49-HNC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjoTWM2OD1zLkezOVg3KM7:TR?= MX7TRW5ITVJ?
NCI-H747 NFLKdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HMVmlEPTB;MT63OVM1PiEQvF2= NGXVdVJUSU6JRWK=
LU-165 M33mW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFwOES5PFYh|ryP MnLVV2FPT0WU
OMC-1 NEH3d3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;KTWM2OD1zLkm1NFY3KM7:TR?= MmnUV2FPT0WU
RCC10RGB MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;mOoZKSzVyPUGuPVU5OTdizszN NVX4S2xYW0GQR1XS
SW684 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwOU[wPVkh|ryP MoXHV2FPT0WU
TE-8 Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHiyW2xKSzVyPUKuNFU2PTlizszN M3XIb3NCVkeHUh?=
SK-N-DZ M{jnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTLT4U6UUN3ME2yMlE{Ojd2IN88US=> NUe1bIt4W0GQR1XS
EVSA-T NFrVN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjuT3RKSzVyPUKuNVc{OTVizszN MnPnV2FPT0WU
KASUMI-1 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG3bGxKSzVyPUKuNVg5OTVizszN MUHTRW5ITVJ?
NKM-1 M2PLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17ndmlEPTB;Mj6yOVQ4OiEQvF2= M4D2c3NCVkeHUh?=
CAL-148 NXrlPYdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq2TWM2OD1{LkOzOlE1KM7:TR?= MWDTRW5ITVJ?
NCI-H64 M1\1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPsTWM2OD1{LkO0NlMzKM7:TR?= MXjTRW5ITVJ?
KNS-81-FD M{jPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PFOWlEPTB;Mj6zOlYzKM7:TR?= M1nuN3NCVkeHUh?=
KM12 MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJwNEC4N|kh|ryP MWXTRW5ITVJ?
SW954 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjWbWFYUUN3ME2yMlQ4Pzd7IN88US=> MW\TRW5ITVJ?
NCI-H1395 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJwNUK2OFUh|ryP MXLTRW5ITVJ?
DJM-1 NFe4PWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJwNkC2N{DPxE1? M1vUUnNCVkeHUh?=
COLO-668 NHe1XXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHJTWM2OD1{LkiyOlk2KM7:TR?= M1\FN3NCVkeHUh?=
NCI-H1436 NXfEZ3c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrsTWM2OD1{Lki1OlE2KM7:TR?= NWS0VohrW0GQR1XS
LB2241-RCC Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;G[GpKSzVyPUKuPFY5OzlizszN NXvkRWNvW0GQR1XS
GT3TKB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\KTWM2OD1{Lki5NFU2KM7:TR?= MlLuV2FPT0WU
COLO-824 M1Wz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJwOEm3Olgh|ryP NFXHdXlUSU6JRWK=
ES1 MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nVd2lEPTB;Mj64PVg4QSEQvF2= M{jM[HNCVkeHUh?=
LB771-HNC NH7CfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fDT2lEPTB;Mj65NFk1PiEQvF2= M3fyOXNCVkeHUh?=
GI-ME-N M{LLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PNcWlEPTB;Mz6wNFkxPCEQvF2= MYjTRW5ITVJ?
NALM-6 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTNwMEC5N|Mh|ryP NYSy[YdqW0GQR1XS
LU-134-A Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC1[2g6UUN3ME2zMlA2PDJ3IN88US=> MoqwV2FPT0WU
DMS-153 NGXjelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\ZfWlEPTB;Mz6wOVgzPCEQvF2= NUO3V5E1W0GQR1XS
MZ1-PC NIP0ZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;QN2lEPTB;Mz6wPVA4QCEQvF2= MUDTRW5ITVJ?
NCI-H1155 NV;ZPW5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTNwMUG2NUDPxE1? NEnQW5hUSU6JRWK=
CAS-1 MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP6TWM2OD1|LkGzO|A4KM7:TR?= M3HSVXNCVkeHUh?=
D-502MG NGfwPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzUfHlJUUN3ME2zMlE1OzlizszN MlTRV2FPT0WU
NCI-H2141 NHPKU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\2PFdGUUN3ME2zMlE4PDV{IN88US=> MnjYV2FPT0WU
NB6 M{ftZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nRWWlEPTB;Mz6xPFI2QSEQvF2= M4G3NXNCVkeHUh?=
NCCIT NYTFZ3dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\Cc3gxUUN3ME2zMlIyQDB7IN88US=> NV23[3d[W0GQR1XS
NB69 M2jBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v5U2lEPTB;Mz6zNVg6OSEQvF2= M4rvbHNCVkeHUh?=
JVM-2 M{HQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPhTWM2OD1|LkO2OFM{KM7:TR?= MknHV2FPT0WU
K052 M4LmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7iTWM2OD1|LkO3PVY5KM7:TR?= MWLTRW5ITVJ?
HCC2157 NWHlZoYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTNwNUOyNlgh|ryP MYXTRW5ITVJ?
KMOE-2 NXXX[Ig{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmyTWM2OD1|LkW0NlQzKM7:TR?= MULTRW5ITVJ?
SF268 NFXPUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\sOW5KUUN3ME2zMlcyPTV2IN88US=> NFH6e2tUSU6JRWK=
CHP-126 NWL1RYhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfOTppKSzVyPUOuO|Y1PThizszN MUXTRW5ITVJ?
CP66-MEL Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETvW3dKSzVyPUOuO|kxQTRizszN NI\we2NUSU6JRWK=
NCI-H69 MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTRwMEG5N|Yh|ryP NV\vVZBIW0GQR1XS
A253 M2jXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTRwMEKxNFEh|ryP MVvTRW5ITVJ?
NB14 Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHNTWM2OD12LkGwOFc6KM7:TR?= NWHobFlmW0GQR1XS
NCI-H1694 NILVOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTRwMUOxNVIh|ryP MkXIV2FPT0WU
NCI-H2196 M2r1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL4RlFKSzVyPUSuNVcyPjlizszN MXPTRW5ITVJ?
TE-9 MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\hTWM2OD12LkG3OVgzKM7:TR?= M2HGcXNCVkeHUh?=
D-283MED MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rzW2lEPTB;ND6xPFg1KM7:TR?= MVfTRW5ITVJ?
OCI-AML2 M{HmbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTRwMUm0PFkh|ryP MorxV2FPT0WU
D-263MG NX3Gc2U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTRwMkK5OlEh|ryP NE\CXWZUSU6JRWK=
MPP-89 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX4TWM2OD12LkK3N|A1KM7:TR?= MonNV2FPT0WU
LAMA-84 M125Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DEOWlEPTB;ND6zNFQzOSEQvF2= NIfXZ|ZUSU6JRWK=
LB373-MEL-D NEjReHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLTTWM2OD12LkO2O|g6KM7:TR?= MljLV2FPT0WU
UACC-257 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HyOGlEPTB;ND6zPVU{PCEQvF2= M4Syd3NCVkeHUh?=
MC-CAR MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PCTmlEPTB;ND60N|k6KM7:TR?= M4\NTXNCVkeHUh?=
COLO-320-HSR M{Dodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Hud2lEPTB;ND60OFQzPyEQvF2= MYPTRW5ITVJ?
P30-OHK MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTRwNk[1PFEh|ryP Mn62V2FPT0WU
UACC-812 NX\ZVYtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRwNkmxOlEh|ryP MYnTRW5ITVJ?
CTB-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTRwN{G1OVUh|ryP NUjDNWZTW0GQR1XS
ALL-PO NH3ubppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[4Z2lEPTB;ND64OFA4PyEQvF2= NVm4VIYxW0GQR1XS
SK-MEL-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TjS2lEPTB;ND64Olk2PSEQvF2= NGC1RnZUSU6JRWK=
TC-YIK NWGxbYh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXvbos2UUN3ME20Mlk4QTR{IN88US=> M37hbXNCVkeHUh?=
NCI-H1882 NE\TeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ntPWlEPTB;NT6wNlAxOSEQvF2= NWHoO29WW0GQR1XS
MHH-CALL-2 MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjScnZKSzVyPUWuNFUxPDJizszN M3vvZXNCVkeHUh?=
U-87-MG NVH6O4t{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fhPGlEPTB;NT6wPVQ3PiEQvF2= NYq0V2VpW0GQR1XS
NCI-H1092 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXMUGJlUUN3ME21MlI3PTV3IN88US=> MnnQV2FPT0WU
TE-441-T NFrOeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ThUmlEPTB;NT6yO|gzKM7:TR?= MXXTRW5ITVJ?
SK-MEL-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3MUm9KSzVyPUWuNlkxPDRizszN M37RVXNCVkeHUh?=
EW-22 M1ixZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XacGlEPTB;NT6yPVQ3PiEQvF2= MXjTRW5ITVJ?
MZ7-mel MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\VTGlEPTB;NT60NFY6OSEQvF2= M2W1[XNCVkeHUh?=
LP-1 NXznSYJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPFWm1KSzVyPUWuOFEzQTFizszN M3nhUHNCVkeHUh?=
NCI-SNU-16 MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTvTWM2OD13Lk[0NFc1KM7:TR?= MXfTRW5ITVJ?
LU-65 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv3OHBQUUN3ME21Mlc3Ozd|IN88US=> MUnTRW5ITVJ?
CW-2 M2\2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rw[2lEPTB;NT64OVk2QSEQvF2= NWDMc|ZSW0GQR1XS
WSU-NHL Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nyeWlEPTB;NT65OVE4PCEQvF2= M4\TRXNCVkeHUh?=
IST-MES1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH0VWJKSzVyPUWuPVU1PDNizszN MYXTRW5ITVJ?
U-266 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTVwOUiyNFIh|ryP MWHTRW5ITVJ?
TALL-1 NU\3WZc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTZwMUS2PFgh|ryP M{LZVHNCVkeHUh?=
Calu-6 NYXtPVA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XDbWlEPTB;Nj6xOVMyPiEQvF2= MoHRV2FPT0WU
MMAC-SF MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjFTWM2OD14LkG4OVU3KM7:TR?= MkHkV2FPT0WU
NCI-H82 NVfKV|JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPoTWM2OD14LkKwOFg6KM7:TR?= NWjqV5N1W0GQR1XS
RS4-11 M2\Bc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfvTWM2OD14LkK1PFk4KM7:TR?= NXHD[4Y2W0GQR1XS
SNU-C2B Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTzcYdkUUN3ME22MlQxQTZ7IN88US=> NUHPW2NtW0GQR1XS
BOKU M4j5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofaTWM2OD14LkS3OVk4KM7:TR?= NYnWNIlZW0GQR1XS
C8166 NH:4ZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HBRWlEPTB;Nj61OVkyOiEQvF2= NH63O3VUSU6JRWK=
D-247MG NX\xO4tIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTdwMESzOFch|ryP MXPTRW5ITVJ?
EW-18 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rWSmlEPTB;Nz6wO|I6OiEQvF2= NYLpfYhoW0GQR1XS
KG-1 NHX1d2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XZcmlEPTB;Nz62Nlc{QCEQvF2= NF\6ZVlUSU6JRWK=
REH NH\zPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H0VmlEPTB;Nz62PFExQSEQvF2= NG\IXmlUSU6JRWK=
U-698-M MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PqXGlEPTB;Nz64OFMyPSEQvF2= NFzpbHNUSU6JRWK=
KP-N-RT-BM-1 MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTdwOUOwNlkh|ryP M4XncXNCVkeHUh?=
MS-1 M3HEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTmVY9tUUN3ME23Mlk3ODRzIN88US=> M33BWHNCVkeHUh?=
SNU-C1 MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rF[2lEPTB;Nz65PFE6OiEQvF2= M4nSXHNCVkeHUh?=
SK-MM-2 M{Hub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRThwMk[wOlUh|ryP MkD0V2FPT0WU
LAN-6 MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XQZmlEPTB;OD6zNFAxOSEQvF2= MnTmV2FPT0WU
NEC8 MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHid5VjUUN3ME24MlMxPjlzIN88US=> NXTzO5hOW0GQR1XS
NCI-H1770 NGjoNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRThwM{iwNFIh|ryP NU\GSXc1W0GQR1XS
D-336MG M4DVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjXSFM4UUN3ME24MlQxOTF4IN88US=> NUnKcY1SW0GQR1XS
COLO-829 NUf4XVU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\UcWlEPTB;OD60PFg4QSEQvF2= MoG2V2FPT0WU
LS-513 NIfnRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7IZZFLUUN3ME24MlU6PTl7IN88US=> MUjTRW5ITVJ?
YT Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPIZZRKSzVyPUiuOlI1OjdizszN MXjTRW5ITVJ?
EW-24 M4DyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRThwN{[1OEDPxE1? Mn7wV2FPT0WU
IST-SL1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvaNYZkUUN3ME24Mlg3PTR|IN88US=> MmrEV2FPT0WU
CA46 NEKzVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvUPGZ[UUN3ME24Mlk2ODl6IN88US=> NWW0Nol4W0GQR1XS
NCI-H1838 M1jLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHK4c2ZKSzVyPUiuPVg3ODJizszN NFP3WZlUSU6JRWK=
NCI-H719 NHTDOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS2UZdKSzVyPUmuNlUzPzlizszN M3vmR3NCVkeHUh?=
HCE-T NWfVPJd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS1RXJKUUN3ME25MlMxQDVzIN88US=> MlfjV2FPT0WU
A498 NES3T4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXIOFlKSzVyPUmuN|YyOjRizszN NUL6XHBSW0GQR1XS
LB831-BLC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUD1WmkxUUN3ME25Mlc3PTJzIN88US=> MVXTRW5ITVJ?
SKM-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofNTWM2OD17Lki1PVY{KM7:TR?= Mo\QV2FPT0WU
THP-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\vXmlEPTB;OT65OlkyQCEQvF2= M2TC[nNCVkeHUh?=
SHP-77 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFyLkSwO{DPxE1? MVzTRW5ITVJ?
EW-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfETGRKSzVyPUGwMlYzQDlizszN M4\0R3NCVkeHUh?=
KY821 M3zlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3e0SWlEPTB;MUCuO|Y{KM7:TR?= NVTU[HJNW0GQR1XS
NCI-SNU-1 M{nLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvhNGtKSzVyPUGxMlAzOTdizszN NEHsboNUSU6JRWK=
HCC2218 NWXEXoNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIixNYZKSzVyPUGxMlM6QDZizszN NFXaT2lUSU6JRWK=
IM-9 NFvhPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzwXGJKSzVyPUGxMlUyODZizszN MkDGV2FPT0WU
NCI-H889 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXmVIxjUUN3ME2xNU42OzF|IN88US=> Ml\lV2FPT0WU
HDLM-2 NEjJSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi5SY9uUUN3ME2xNk41OTV7IN88US=> M1fWWHNCVkeHUh?=
LB2518-MEL MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LaXGlEPTB;MUKuOlgyPSEQvF2= M4Xu[3NCVkeHUh?=
NCI-H23 M1zubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljwTWM2OD1zMz6yOFI2KM7:TR?= MVjTRW5ITVJ?
NB17 MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjJXI1EUUN3ME2xN{41PTd7IN88US=> MYPTRW5ITVJ?
NCI-H322M MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfkUW1KSzVyPUG0MlQxPjhizszN MkK1V2FPT0WU
SUP-T1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLGW242UUN3ME2xOE41OTNizszN MoC3V2FPT0WU
ES3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL1ZWR5UUN3ME2xOU4xPzB|IN88US=> NWXndXp5W0GQR1XS
ES5 M3f4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF3LkC3PFch|ryP Mm\RV2FPT0WU
NCI-H1650 NWC0dolYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3yTWM2OD1zNT60PVc6KM7:TR?= NV7QRYdVW0GQR1XS
NCI-H226 MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\jTWM2OD1zNT64O|Y5KM7:TR?= NIn3VphUSU6JRWK=
COR-L88 NUfqeolRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELJ[4RKSzVyPUG2MlMyPCEQvF2= NX75c4xCW0GQR1XS
SCC-15 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\2TWM2OD1zNj6zPFY6KM7:TR?= M{XzSXNCVkeHUh?=
GOTO M4i2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTzcWxKSzVyPUG2MlQ4QTNizszN MkfNV2FPT0WU
SIMA NXvQTVZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrrWFBKSzVyPUG2MlQ5ODJizszN NUToRnhTW0GQR1XS
NCI-H1299 MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIS5WYtKSzVyPUG3MlE2QTFizszN M1TO[nNCVkeHUh?=
NCI-H1581 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK3dGpHUUN3ME2xO{41OjF7IN88US=> NIizTGRUSU6JRWK=
MHH-NB-11 NIjUOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rm[2lEPTB;MUeuPVY5OyEQvF2= NVXhTJBRW0GQR1XS
MFM-223 M4PKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfEbYlKSzVyPUG4MlA2OzhizszN M4\jT3NCVkeHUh?=
ES7 NW\1cmtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LSZmlEPTB;MUiuOVQ{OSEQvF2= M3njWnNCVkeHUh?=
JVM-3 NIPmboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TBe2lEPTB;MUiuO|E4KM7:TR?= MlXIV2FPT0WU
RL NX3vfoo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPQbZJKSzVyPUKwMlM5QCEQvF2= Mlf4V2FPT0WU
EC-GI-10 NGDkT|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fSO2lEPTB;MkGuNlA1OSEQvF2= M{D1d3NCVkeHUh?=
LNCaP-Clone-FGC NX[zN4ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\UTWM2OD1{MT62O|Y5KM7:TR?= NVX3RolLW0GQR1XS
IMR-5 MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi4eIZKSzVyPUKxMlg1QTRizszN NWrMc5dKW0GQR1XS
KP-N-YS MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe3cplLUUN3ME2yNU45PzVizszN NYX5S49FW0GQR1XS
Mo-T M3\OZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7wTWM2OD1{Mj6yNVg2KM7:TR?= M16yZ3NCVkeHUh?=
NCI-H128 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJ|LkW4OVMh|ryP NVTHe|k5W0GQR1XS
RH-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r1WWlEPTB;MkOuO|g3PiEQvF2= NF7DOm9USU6JRWK=
NCI-H2171 M1;4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjSTWM2OD1{ND6yOFg2KM7:TR?= MV\TRW5ITVJ?
RPMI-8866 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[1TWM2OD1{Nj63OFIh|ryP MYrTRW5ITVJ?
SK-N-FI MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvOc5BXUUN3ME2yO{4{QDFzIN88US=> NYT0dYVYW0GQR1XS
LOXIMVI MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf2VolKSzVyPUK3MlgxPTFizszN MYnTRW5ITVJ?
P31-FUJ NVrGXohjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjmZnNCUUN3ME2zNU42Ozd2IN88US=> NGHDTFFUSU6JRWK=
KMS-12-PE MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrBTWM2OD12OT61N|AzKM7:TR?= NELGVGhUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% CMC+0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

カスタマーフィードバック (12)


Click to enlarge
Rating
Source Nat Genet, 2014, 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell, 2011, 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res, 2012, 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source Autophagy, 2015, 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck
Method Cell imaging
Cell Lines H4-LC3-GFP cells
Concentrations 200 nM
Incubation Time 24 h
Results Consistent with inhibition of autophagy, the levels of LC3-II were lower and the levels of SQSTM1/p62 were higher in this USP18 knockdown cell line compared to that of control under basal conditions as well as the induced condition after the treatment with rapamycin.

Click to enlarge
Rating
Source Cell Rep, 2015, 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 250 nM
Incubation Time 24 h
Results Rapamycin virtually abolishes stimulation by Rheb of phospho-S6 kinase and phospho-4EBP1 but has negligible effects on phospho-eIF2a (A). In contrast to phosphorylation of eIF2a, which is not mediated by mTORC1, phosphorylation of other elongation factors does involve mTORC1. Thus, rapamycin prevents phosphorylation of eIF4G and eIF4B, targets of S6K, but not eIF2a (B). By contrast, rapamycin, as expected, abolishes phospho-S6 kinase but fails to influence phospho-eIF2a, phospho-Erk or phospho-Akt (C).

Click to enlarge
Rating
Source Biochem Pharmacol, 2015, 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck
Method Immunofluorescence
Cell Lines RAW264.7 cells
Concentrations 10 uM
Incubation Time 16 h
Results It has been reported that autophagy can directly regulate inflammatory responses. To confirm this phenomenon, we pre-treated RAW264.7 cells with 3-MA (an autophagy inhibitor by blocking the class III PI3Ks) or rapamycin (an autophagy inducer by targeting the negative regulators against autophagy as mammalian target of rapamycin (mTOR)), followed by addition of LPS. LPS-induced punctate LC3 was markedly reduced and enhanced in the presence of 3-MA and rapamycin, respectively.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source J Lipid Res, 2011, 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochim Biophys Acta, 2013, 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis, 2013, 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2011, Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Click to enlarge
Rating
Source 2013, Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

文献中の引用 (62)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ